Neck masses differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 13: Line 13:
! colspan="2" rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! colspan="2" rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign/Malignant
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign/Malignant
! colspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestation
! colspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestation
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Paraclinical findings
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Paraclinical findings
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard diagnosis
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard diagnosis
Line 21: Line 21:
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab findings
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab findings
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
Line 29: Line 29:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mass exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mass exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin changes
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |LAP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |LAP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Others
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Others
Line 51: Line 50:
*Non-pulsatile
*Non-pulsatile
*Fluctuant
*Fluctuant
| align="left" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*A pit at the opening of the [[cyst]]
*A pit at the opening of the [[cyst]]
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 82: Line 80:


*Moves upwards with [[tongue]] protrusion and [[swallowing]]
*Moves upwards with [[tongue]] protrusion and [[swallowing]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
Line 107: Line 104:
*[[Females]]>[[males]]
*[[Females]]>[[males]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Presents with a flat red or purple patch
*Presents with a flat red or purple patch
*Regress gradually with age
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
Line 116: Line 114:


*Well-demarcated
*Well-demarcated
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*[[Blanching]]
*[[Blanching]]
Line 122: Line 121:


*[[Erythematous]] patch
*[[Erythematous]] patch
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |Regress gradually with age
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*GLUT-1
*GLUT-1
Line 163: Line 160:


*AV malformations: [[Thrill]], warm, [[Pulsatile Flow|pulsatile]]
*AV malformations: [[Thrill]], warm, [[Pulsatile Flow|pulsatile]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Grow proportionally with age
*Grow proportionally with age
Line 200: Line 196:


*[[Transillumination]]+
*[[Transillumination]]+
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Never regress, expand/contract based on [[inflammation]]
*Never regress, expand/contract based on [[inflammation]]
Line 236: Line 231:


*Increase in size on [[valsalva]]
*Increase in size on [[valsalva]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Common in glass blowers, trumpet players
*Common in glass blowers, trumpet players
Line 268: Line 262:
*Fluctuant
*Fluctuant
*Soft
*Soft
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
Line 292: Line 285:


*Non-tender
*Non-tender
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 325: Line 317:


*Noncompressible
*Noncompressible
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Usually normal/sometimes a pit or [[sinus]] is seen
*Usually normal/sometimes a pit or [[sinus]] is seen


*A tuft of [[hair]] at the center of the pit for [[nasal]] [[Dermoid cyst|dermoid]] [[cyst]]
*A tuft of [[hair]] at the center of the pit for [[nasal]] [[Dermoid cyst|dermoid]] [[cyst]]
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 358: Line 349:


*Compressible
*Compressible
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
Line 381: Line 371:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mass exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mass exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin changes
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |LAP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |LAP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Others
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Others
Line 411: Line 400:
*[[Purulent]] [[discharge]] expressed from the [[duct]]
*[[Purulent]] [[discharge]] expressed from the [[duct]]
*Smooth
*Smooth
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Redness
*Redness
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
*More common in people with bad [[oral hygiene]]
*More common in people with bad [[oral hygiene]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 445: Line 433:


*Smooth
*Smooth
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Mostly due to [[obstruction]] by a stone or [[stricture]]
*Mostly due to [[obstruction]] by a stone or [[stricture]]
Line 475: Line 462:
*Non-tender
*Non-tender
*Soft
*Soft
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Generalized/[[cervical]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
*Generalized/cervical lymphadenopathy
| align="center" style="background:#F5F5F5;" |↑[[ESR]]
| align="center" style="background:#F5F5F5;" |↑[[ESR]]
↑[[SGOT]]/[[SGPT]]
↑[[SGOT]]/[[SGPT]]
Line 510: Line 496:
*Non-tender
*Non-tender
*Firm
*Firm
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |<nowiki/>
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*B/L [[posterior]] [[cervical]], [[Axillary|axillar]]<nowiki/>y, [[inguinal]]
*B/L [[posterior]] [[cervical]], [[Axillary|axillar]]<nowiki/>y, [[inguinal]] lymphadenopathy
| align="center" style="background:#F5F5F5;" | -
**[[Ulcer]]/[[rash]]
 
**[[Redness]] 
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Atypical [[lymphocytosis]]
*Atypical [[lymphocytosis|lymphocytosi]]<nowiki/>[[lymphocytosis|s]]


*+ Monospot test
*+ Monospot test
Line 543: Line 531:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |Non-tender
| align="center" style="background:#F5F5F5;" |Non-tender
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Generalized
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
*Generalized lymphadenopathy
| align="center" style="background:#F5F5F5;" |↓ [[Leukopenia|CD4+ Tcells]]
| align="center" style="background:#F5F5F5;" |↓ [[Leukopenia|CD4+ Tcells]]
[[Thrombocytopenia]]
[[Thrombocytopenia]]
Line 578: Line 565:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Non-tender
*Non-tender
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Mild [[cervical]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
*Mild cervical lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*[[Lymphocytosis]]
*[[Lymphocytosis]]
Line 615: Line 601:
*Edematous
*Edematous
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*[[Ulcer]]/[[rash]]
*[[Redness]]
| align="center" style="background:#F5F5F5;" |
*Regional
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*↑[[ESR]]
*↑[[ESR]]


*↑[[C-reactive protein (CRP)|C-reactive protein]]
*↑[[C-reactive protein (CRP)|C-reactive protein]]
*Regional lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*[[Caseating]] [[granuloma]] +/- [[multinucleated giant cells]]
*[[Caseating]] [[granuloma]] +/- [[multinucleated giant cells]]
Line 646: Line 627:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*[[Tenderness|Tender]]
*[[Tenderness|Tender]]
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*[[Cervical]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
*Cervical lymphadenopathy
| align="center" style="background:#F5F5F5;" |↑[[ESR]]
| align="center" style="background:#F5F5F5;" |↑[[ESR]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 675: Line 655:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Tender [[cervical]] [[Lymph node|nodes]]
* Tender [[cervical]] [[Lymph node|nodes]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Vesicular]]
* [[Vesicular]]
Line 680: Line 661:
* [[Erythema]]   
* [[Erythema]]   
* [[Papule]] at site of inoculation
* [[Papule]] at site of inoculation
| align="center" style="background:#F5F5F5;" | +
* Lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* ↑ [[ESR]]
* ↑ [[ESR]]
Line 718: Line 698:


* Non-tender at late stage
* Non-tender at late stage
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Red
* Red


* Blue
* Blue
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* ↑ [[ESR]]
* ↑ [[ESR]]
Line 760: Line 739:
* Non-tender
* Non-tender
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Induration|Indurated]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[PPD-tuberculin skin test|PPD]]: +
* [[PPD-tuberculin skin test|PPD]]: +
Line 798: Line 776:
* Tender [[anterior]] cervical nodes
* Tender [[anterior]] cervical nodes
* [[Tonsillar Disease|Tonsillar]] exudates
* [[Tonsillar Disease|Tonsillar]] exudates
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Rapid [[antigen]] detection [[Test|tests]]: +/-
* Rapid [[antigen]] detection [[Test|tests]]: +/-
Line 841: Line 819:


* Non-fluctuant
* Non-fluctuant
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Serology]] :  
* [[Serology]] :  
Line 877: Line 855:


* Non-tender [[parotid glands]]
* Non-tender [[parotid glands]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Erythema nodosum]]
* [[Erythema nodosum]]


* [[Lupus]] pernios
* [[Lupus]] pernios
| align="center" style="background:#F5F5F5;" | +
* Lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* ↑ [[ESR]]
* ↑ [[ESR]]
Line 920: Line 898:


* B/L enlarged [[parotid glands]]
* B/L enlarged [[parotid glands]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Pruritis]]
* [[Pruritis]]
Line 925: Line 904:


* Dry
* Dry
| align="center" style="background:#F5F5F5;" | +
* Lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[ESR|↑ ESR]]
* [[ESR|↑ ESR]]
Line 957: Line 935:
* Non tender [[Cervical|cervical node]]
* Non tender [[Cervical|cervical node]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Papule]]
* Cherry hemangiomata
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Lymphadenopathy
** [[Papule]]
** Cherry hemangiomata
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* ↑ [[ESR]]
* ↑ [[ESR]]
Line 997: Line 975:
* Tender [[Cervical|cervical nodes]]
* Tender [[Cervical|cervical nodes]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[rashes]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Skin rash
* Lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* ↑ [[ESR]]
* ↑ [[ESR]]
Line 1,028: Line 1,006:


* Non-tender [[Cervical|cervical node]]
* Non-tender [[Cervical|cervical node]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Itching]]
* [[Itching]]
| align="center" style="background:#F5F5F5;" | +
* Lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |↑ [[Eosinophils]]
| align="center" style="background:#F5F5F5;" |↑ [[Eosinophils]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 1,061: Line 1,039:
* Non-tender enlarged [[cervical lymph nodes]]
* Non-tender enlarged [[cervical lymph nodes]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Erythema]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Itching|Erythema]]
* Lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* ↑ [[ESR]]
* ↑ [[ESR]]
Line 1,100: Line 1,078:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Large, single palpable [[Cervical|cervical node]]
* Large, single palpable [[Cervical|cervical node]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Rashes]]
* [[Rashes]]


* [[Desquamation]] of skin
* [[Desquamation]] of skin
| align="center" style="background:#F5F5F5;" | +
* Lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* ↑ [[ESR]]
* ↑ [[ESR]]
Line 1,129: Line 1,107:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mass exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mass exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin changes
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |LAP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |LAP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Others
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Others
Line 1,138: Line 1,115:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
|-
! rowspan="20" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Neoplasm
! rowspan="19" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Neoplasm
! colspan="2" align="center" style="background:#DCDCDC;" |[[Hypopharyngeal cancer]]<ref name="pmid12560383">{{cite journal |vauthors=Helliwell TR |title=acp Best Practice No 169. Evidence based pathology: squamous carcinoma of the hypopharynx |journal=J. Clin. Pathol. |volume=56 |issue=2 |pages=81–5 |date=February 2003 |pmid=12560383 |pmc=1769882 |doi= |url=}}</ref><ref>{{cite journal|journal=International Journal of Recent Scientific Research|issn=09763031|doi=10.24327/IJRSR}}</ref><ref name="Maaslandvan den Brandt2014">{{cite journal|last1=Maasland|first1=Denise HE|last2=van den Brandt|first2=Piet A|last3=Kremer|first3=Bernd|last4=Goldbohm|first4=R Alexandra|last5=Schouten|first5=Leo J|title=Alcohol consumption, cigarette smoking and the risk of subtypes of head-neck cancer: results from the Netherlands Cohort Study|journal=BMC Cancer|volume=14|issue=1|year=2014|issn=1471-2407|doi=10.1186/1471-2407-14-187}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Hypopharyngeal cancer]]<ref name="pmid12560383">{{cite journal |vauthors=Helliwell TR |title=acp Best Practice No 169. Evidence based pathology: squamous carcinoma of the hypopharynx |journal=J. Clin. Pathol. |volume=56 |issue=2 |pages=81–5 |date=February 2003 |pmid=12560383 |pmc=1769882 |doi= |url=}}</ref><ref>{{cite journal|journal=International Journal of Recent Scientific Research|issn=09763031|doi=10.24327/IJRSR}}</ref><ref name="Maaslandvan den Brandt2014">{{cite journal|last1=Maasland|first1=Denise HE|last2=van den Brandt|first2=Piet A|last3=Kremer|first3=Bernd|last4=Goldbohm|first4=R Alexandra|last5=Schouten|first5=Leo J|title=Alcohol consumption, cigarette smoking and the risk of subtypes of head-neck cancer: results from the Netherlands Cohort Study|journal=BMC Cancer|volume=14|issue=1|year=2014|issn=1471-2407|doi=10.1186/1471-2407-14-187}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 1,158: Line 1,135:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Non tender [[Cervical|cervical node]]
* Non tender [[Cervical|cervical node]]
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Lymphadenopathy]]
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 1,178: Line 1,155:
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
|-
|-
! rowspan="10" align="center" style="background:#DCDCDC;" |[[Salivary gland neoplasm]]
! rowspan="9" align="center" style="background:#DCDCDC;" |[[Salivary gland neoplasm]]
! align="center" style="background:#DCDCDC;" |[[Pleomorphic adenoma]]<ref name="pmid22190789">{{cite journal |vauthors=Debnath SC, Adhyapok AK |title=Pleomorphic adenoma (benign mixed tumour) of the minor salivary glands of the upper lip |journal=J Maxillofac Oral Surg |volume=9 |issue=2 |pages=205–8 |date=June 2010 |pmid=22190789 |pmc=3244097 |doi=10.1007/s12663-010-0052-5 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Pleomorphic adenoma]]<ref name="pmid22190789">{{cite journal |vauthors=Debnath SC, Adhyapok AK |title=Pleomorphic adenoma (benign mixed tumour) of the minor salivary glands of the upper lip |journal=J Maxillofac Oral Surg |volume=9 |issue=2 |pages=205–8 |date=June 2010 |pmid=22190789 |pmc=3244097 |doi=10.1007/s12663-010-0052-5 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 1,203: Line 1,180:


* Mobile
* Mobile
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 1,241: Line 1,217:


* [[Solitary]]
* [[Solitary]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 1,258: Line 1,233:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Biopsy]]
* [[Biopsy]]
| align="center" style="background:#F5F5F5;" |
|-
! align="center" style="background:#DCDCDC;" |Lymphoepithelioma
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
Line 1,291: Line 1,250:
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" |[[Firm]], multilobulated and mobile [[mass]]
| align="center" style="background:#F5F5F5;" |[[Firm]], multilobulated and mobile [[mass]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Normal
*Normal
Line 1,297: Line 1,257:
*[[Swelling]]
*[[Swelling]]
*Skin [[ulceration]]
*Skin [[ulceration]]
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Normal
*Normal
Line 1,333: Line 1,291:
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" |[[Nodular]] and fluctuant [[swelling]]
| align="center" style="background:#F5F5F5;" |[[Nodular]] and fluctuant [[swelling]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Normal
*Normal
Line 1,338: Line 1,297:
*Redness
*Redness
*Skin [[ulceration]]
*Skin [[ulceration]]
| align="center" style="background:#F5F5F5;" | +/-
*May have lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |Normal
| align="center" style="background:#F5F5F5;" |Normal
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 1,372: Line 1,330:
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" |[[Cystic]] and [[Mass|solid mass]]
| align="center" style="background:#F5F5F5;" |[[Cystic]] and [[Mass|solid mass]]
| align="center" style="background:#F5F5F5;" |Normal
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | +/-
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |Association with [[CMV]]
* May have lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |[[Gross examination|Gross findings]]:
| align="center" style="background:#F5F5F5;" |[[Gross examination|Gross findings]]:
Line 1,385: Line 1,343:
| align="center" style="background:#F5F5F5;" |cystic and solid component with variable appearance
| align="center" style="background:#F5F5F5;" |cystic and solid component with variable appearance
| align="center" style="background:#F5F5F5;" |Incisional [[biopsy]] and [[Histopathological|histopathological examination]]
| align="center" style="background:#F5F5F5;" |Incisional [[biopsy]] and [[Histopathological|histopathological examination]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |Association with [[CMV]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Adenoid cystic cancer|Adenoid cystic carcinoma]] <ref name="pmid17825603">{{cite journal |vauthors=Jones AV, Craig GT, Speight PM, Franklin CD |title=The range and demographics of salivary gland tumours diagnosed in a UK population |journal=Oral Oncol. |volume=44 |issue=4 |pages=407–17 |date=April 2008 |pmid=17825603 |doi=10.1016/j.oraloncology.2007.05.010 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Adenoid cystic cancer|Adenoid cystic carcinoma]] <ref name="pmid17825603">{{cite journal |vauthors=Jones AV, Craig GT, Speight PM, Franklin CD |title=The range and demographics of salivary gland tumours diagnosed in a UK population |journal=Oral Oncol. |volume=44 |issue=4 |pages=407–17 |date=April 2008 |pmid=17825603 |doi=10.1016/j.oraloncology.2007.05.010 |url=}}</ref>
Line 1,391: Line 1,349:
| align="center" style="background:#F5F5F5;" |Age: 40s to 60s
| align="center" style="background:#F5F5F5;" |Age: 40s to 60s
Gender: Female predominance
Gender: Female predominance
| align="center" style="background:#F5F5F5;" |Slow growing painless [[mass]]
| align="center" style="background:#F5F5F5;" |
* Slow growing rare tumor with low [[Recurrence plot|recurrence]]
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" |Solid [[mass]]
| align="center" style="background:#F5F5F5;" |Solid [[mass]]
| align="center" style="background:#F5F5F5;" |Normal to [[Ulcerated lesion|ulcerated lesions]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | +/-
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |Slow growing  rare tumor with low [[Recurrence plot|recurrence]]
* Normal to [[Ulcerated lesion|ulcerated lesions]]
* May have lymphadenopathy
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |[[Gross]] findings: Tubular, cribriform and solid pattern of growth
| align="center" style="background:#F5F5F5;" |[[Gross]] findings: Tubular, cribriform and solid pattern of growth
Line 1,415: Line 1,375:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |Small [[nodules]] and [[oral cavity]] with or without [[lymphadenopathy]]
| align="center" style="background:#F5F5F5;" |Small [[nodules]] and [[oral cavity]] with or without [[lymphadenopathy]]
| align="center" style="background:#F5F5F5;" |[[Skin]] stays intact or may show some [[ulceration]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | +/-
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |There are several subtypes of [[adenocarcinoma]].
* Normal to [[Ulcerated lesion|ulcerated lesions]]
Some are more infiltrating in nature
* May have lymphadenopathy
| align="center" style="background:#F5F5F5;" |Can be normal or may show [[anemia]] and blood cell disorders with distant bone [[invasion]]
| align="center" style="background:#F5F5F5;" |Can be normal or may show [[anemia]] and blood cell disorders with distant bone [[invasion]]
| align="center" style="background:#F5F5F5;" |On [[histology]] it is confused with Adeocyctic [[carcinoma]] with components of gland and cyst formations.
| align="center" style="background:#F5F5F5;" |On [[histology]] it is confused with Adeocyctic [[carcinoma]] with components of gland and cyst formations.
Line 1,434: Line 1,394:


Mean age: 55 to 61 years
Mean age: 55 to 61 years
| align="center" style="background:#F5F5F5;" |Presents as rapidly growing [[mass]]
| align="center" style="background:#F5F5F5;" |
* Rapidly growing [[mass]] with jaw involvement
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" | ±
Line 1,441: Line 1,402:


*In case of facial nerve involvement may present with [[facial paralysis]]
*In case of facial nerve involvement may present with [[facial paralysis]]
| align="center" style="background:#F5F5F5;" |Jaw involvement results in [[ulceration]] of [[mucosa]] and may cause [[Ulceration|ulceration of skin]] as well
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | +/-
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |Rapidly growing [[mass]] with jaw involvement and [[facial paralysis]] in case of [[facial nerve]] involvement
* Ulceration of [[mucosa]] and [[Ulceration|skin]]
* May have lymphadenopathy
* [[facial paralysis]] in case of [[facial nerve]] involvement
| align="center" style="background:#F5F5F5;" |[[Pathology|Patho]]<nowiki/>morphologically [[tumor]] of [[Salivary gland|salivary ducts]] resembles tumor of [[breast]] ducts, and that where it name is derived from<nowiki/>
| align="center" style="background:#F5F5F5;" |[[Pathology|Patho]]<nowiki/>morphologically [[tumor]] of [[Salivary gland|salivary ducts]] resembles tumor of [[breast]] ducts, and that where it name is derived from<nowiki/>
| align="center" style="background:#F5F5F5;" |[[Gross examination|Gross]] findings:
| align="center" style="background:#F5F5F5;" |[[Gross examination|Gross]] findings:
Line 1,470: Line 1,433:
*Firm
*Firm
*[[Swelling|Solitary swelling]] on jaw
*[[Swelling|Solitary swelling]] on jaw
| align="center" style="background:#F5F5F5;" |Thinning and discoloration of [[skin]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |[[Submandibular gland]] predilection
| align="center" style="background:#F5F5F5;" |[[Submandibular gland]] predilection
Thinning and discoloration of [[skin]]
| align="center" style="background:#F5F5F5;" |Past radiation exposure is a strong [[risk factor]]
| align="center" style="background:#F5F5F5;" |Past radiation exposure is a strong [[risk factor]]
| align="center" style="background:#F5F5F5;" |[[Gross]] findings: Shows skin tissue and thinning of [[skin]]
| align="center" style="background:#F5F5F5;" |[[Gross]] findings: Shows skin tissue and thinning of [[skin]]
Line 1,495: Line 1,458:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Presents with the [[hyperparathyroidism]]
*Presents with the [[hyperparathyroidism]]
*[[Tachycardia]]
*[[Weight loss]]
*[[Sweating]]
*Neck [[swelling]]
*Bone pains
*Bone pains
*Stomach pain
*Stomach pain
Line 1,507: Line 1,466:
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |Lower [[Neck masses|neck mass]] with
| align="center" style="background:#F5F5F5;" |Lower [[Neck masses|neck mass]]
| align="center" style="background:#F5F5F5;" |Skin stays intact most of the time
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |Labs may show [[hypercalcemia]] and its consequences such as [[pancreatitis]] and decrease [[bone density]] on [[DEXA scan]].
*[[Tachycardia]]
*[[Weight loss]]
*[[Sweating]]
*Neck [[swelling]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Low [[TSH]]
*Low [[TSH]]
Line 1,525: Line 1,487:
<ref name="pmid174004872">{{cite journal |vauthors=Sajid MS, Hamilton G, Baker DM |title=A multicenter review of carotid body tumour management |journal=Eur J Vasc Endovasc Surg |volume=34 |issue=2 |pages=127–30 |date=August 2007 |pmid=17400487 |doi=10.1016/j.ejvs.2007.01.015 |url=}}</ref><ref name="pmid158837112">{{cite journal |vauthors=Boedeker CC, Ridder GJ, Schipper J |title=Paragangliomas of the head and neck: diagnosis and treatment |journal=Fam. Cancer |volume=4 |issue=1 |pages=55–9 |date=2005 |pmid=15883711 |doi=10.1007/s10689-004-2154-z |url=}}</ref><ref name="pmid15063383">{{cite journal |vauthors=Pellitteri PK, Rinaldo A, Myssiorek D, Gary Jackson C, Bradley PJ, Devaney KO, Shaha AR, Netterville JL, Manni JJ, Ferlito A |title=Paragangliomas of the head and neck |journal=Oral Oncol. |volume=40 |issue=6 |pages=563–75 |date=July 2004 |pmid=15063383 |doi=10.1016/j.oraloncology.2003.09.004 |url=}}</ref><ref name="pmid28478173">{{cite journal |vauthors=Darouassi Y, Alaoui M, Mliha Touati M, Al Maghraoui O, En-Nouali A, Bouaity B, Ammar H |title=Carotid Body Tumors: A Case Series and Review of the Literature |journal=Ann Vasc Surg |volume=43 |issue= |pages=265–271 |date=August 2017 |pmid=28478173 |doi=10.1016/j.avsg.2017.03.167 |url=}}</ref>
<ref name="pmid174004872">{{cite journal |vauthors=Sajid MS, Hamilton G, Baker DM |title=A multicenter review of carotid body tumour management |journal=Eur J Vasc Endovasc Surg |volume=34 |issue=2 |pages=127–30 |date=August 2007 |pmid=17400487 |doi=10.1016/j.ejvs.2007.01.015 |url=}}</ref><ref name="pmid158837112">{{cite journal |vauthors=Boedeker CC, Ridder GJ, Schipper J |title=Paragangliomas of the head and neck: diagnosis and treatment |journal=Fam. Cancer |volume=4 |issue=1 |pages=55–9 |date=2005 |pmid=15883711 |doi=10.1007/s10689-004-2154-z |url=}}</ref><ref name="pmid15063383">{{cite journal |vauthors=Pellitteri PK, Rinaldo A, Myssiorek D, Gary Jackson C, Bradley PJ, Devaney KO, Shaha AR, Netterville JL, Manni JJ, Ferlito A |title=Paragangliomas of the head and neck |journal=Oral Oncol. |volume=40 |issue=6 |pages=563–75 |date=July 2004 |pmid=15063383 |doi=10.1016/j.oraloncology.2003.09.004 |url=}}</ref><ref name="pmid28478173">{{cite journal |vauthors=Darouassi Y, Alaoui M, Mliha Touati M, Al Maghraoui O, En-Nouali A, Bouaity B, Ammar H |title=Carotid Body Tumors: A Case Series and Review of the Literature |journal=Ann Vasc Surg |volume=43 |issue= |pages=265–271 |date=August 2017 |pmid=28478173 |doi=10.1016/j.avsg.2017.03.167 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |[[Benign]]
| align="center" style="background:#F5F5F5;" |[[Benign]]
| align="center" style="background:#F5F5F5;" |Age: 26-55 years
Gender: Male predominance
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*A slow growing pulsating and expanding [[Neck masses|neck mass]]
* Age: 26-55 years
*pain
* Male predominance
*Change in voice
| align="center" style="background:#F5F5F5;" |
*[[Dizziness]]
*A slow growing [[Neck masses|neck mass]]
*[[Tinnitus]]
*[[Headache]]


*
*
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*Mobile non-tender [[Neck masses|neck mass]] (horizontally more than vertically)
*Mobile non-tender [[Neck masses|neck mass]] (horizontally more than vertically)
*
*
*[[Pulsatile Flow|Pulsatile]] nodule in [[neck]]
*[[Pulsatile Flow|Pulsatile]]  


*[[Bruit]] may be present
*[[Bruit]] may be present
| align="center" style="background:#F5F5F5;" |Normal
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |Urine analysis for [[metanephrine]] levels
*Change in voice
*[[Dizziness]]
*[[Tinnitus]]
*[[Headache]]
| align="center" style="background:#F5F5F5;" |May show Increased [[catecholamine]] levels
| align="center" style="background:#F5F5F5;" |May show Increased [[catecholamine]] levels
| align="center" style="background:#F5F5F5;" |Microscopically they are extra- adrenal [[paragangliomas]]
| align="center" style="background:#F5F5F5;" |Microscopically they are extra- adrenal [[paragangliomas]]
Line 1,560: Line 1,521:
| align="center" style="background:#F5F5F5;" |[[Benign]] (Majority)
| align="center" style="background:#F5F5F5;" |[[Benign]] (Majority)
[[Malignant]] (rare)
[[Malignant]] (rare)
| align="center" style="background:#F5F5F5;" |Mean age:age from 50 to 70 years
| align="center" style="background:#F5F5F5;" |
Gender: More in females
* Age 50-70 years
* More in females
| align="center" style="background:#F5F5F5;" |May be an accidental finding depending on their secretory nature or present with following symptoms:
| align="center" style="background:#F5F5F5;" |May be an accidental finding depending on their secretory nature or present with following symptoms:
*[[Palpitation|Palpitations]]
*[[Palpitation|Palpitations]]
Line 1,577: Line 1,539:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |No visible [[mass]] as they are located deep in the the [[neck]] along the [[Glossopharyngeal nerve|glossopharyngeal]] and [[Vagal nerve|vagal nerves]].
| align="center" style="background:#F5F5F5;" |No visible [[mass]] as they are located deep in the the [[neck]] along the [[Glossopharyngeal nerve|glossopharyngeal]] and [[Vagal nerve|vagal nerves]].
| align="center" style="background:#F5F5F5;" |skin stays intact and usually is normal
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |Associated with some hereditary syndromes and  [[Multiple endocrine neoplasia type 2|MEN2B]] syndrome,  [[Neurofibromatosis type 1]] and [[VHL syndrome|VHL]] disease
| align="center" style="background:#F5F5F5;" |Associated with some hereditary syndromes and  [[Multiple endocrine neoplasia type 2|MEN2B]] syndrome,  [[Neurofibromatosis type 1]] and [[VHL syndrome|VHL]] disease
| align="center" style="background:#F5F5F5;" |[[Biochemical testing]] may show [[catecholamine]] metabolites in serum or urine samples
| align="center" style="background:#F5F5F5;" |[[Biochemical testing]] may show [[catecholamine]] metabolites in serum or urine samples
Line 1,626: Line 1,587:
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" |Multiple slow growing  [[nodules]] on the skin
| align="center" style="background:#F5F5F5;" |Multiple slow growing  [[nodules]] on the skin
| align="center" style="background:#F5F5F5;" |Normal
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |Associated with [[neurofibromatosis type II]].
| align="center" style="background:#F5F5F5;" |Associated with [[neurofibromatosis type II]].


Line 1,666: Line 1,626:
* [[Ascites]]
* [[Ascites]]
* [[Auscultation|Chest auscultation]] may show [[crackles]] and [[fibrosis]]
* [[Auscultation|Chest auscultation]] may show [[crackles]] and [[fibrosis]]
| align="center" style="background:#F5F5F5;" |[[Rash]] and [[pruritus]]
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
With acquired form of C1 inhibitor deficiency patients may develop [[angioedema]]
| align="center" style="background:#F5F5F5;" |
* With acquired form of C1 inhibitor deficiency patients may develop [[angioedema]]
* [[Rash]] and [[pruritus]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Anemia]]
* [[Anemia]]
Line 1,708: Line 1,668:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |Mobile soft [[mass]] with intact overlying skin and in some cases with blue discoloration due to intra-lesion [[hemorrhage]]
| align="center" style="background:#F5F5F5;" |Mobile soft [[mass]] with intact overlying skin and in some cases with blue discoloration due to intra-lesion [[hemorrhage]]
| align="center" style="background:#F5F5F5;" |Intact and normal color
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
* Intact skin and normal color
| align="center" style="background:#F5F5F5;" |Normal
| align="center" style="background:#F5F5F5;" |Normal
| align="center" style="background:#F5F5F5;" |[[Gross examination|Gross]] findings:
| align="center" style="background:#F5F5F5;" |[[Gross examination|Gross]] findings:
Line 1,740: Line 1,700:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |Mobile soft nodule with intact overlying skin
| align="center" style="background:#F5F5F5;" |Mobile soft nodule with intact overlying skin
| align="center" style="background:#F5F5F5;" |Intact and normal in color
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |Multiple [[lipomas]] are associated with [[familial]] multiple lipomatosis
* Intact skin and normal color
| align="center" style="background:#F5F5F5;" |Normal
| align="center" style="background:#F5F5F5;" |Normal
| align="center" style="background:#F5F5F5;" |Diagnoses is usually [[clinical]] but tissue [[biopsy]] may show  
| align="center" style="background:#F5F5F5;" |Diagnoses is usually [[clinical]] but tissue [[biopsy]] may show  
Line 1,753: Line 1,713:


and tissue [[biopsy]]
and tissue [[biopsy]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" | Multiple [[lipomas]] are associated with [[familial]] multiple lipomatosis
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Glomus vagale, [[Glomus jugulare tumor|glomus jugulare]] tumors
! colspan="2" align="center" style="background:#DCDCDC;" |Glomus vagale, [[Glomus jugulare tumor|glomus jugulare]] tumors
Line 1,777: Line 1,737:
* Absent [[thrill]] or [[bruit]] differentiate it from [[Aneurysm|carotid aneurysm]].
* Absent [[thrill]] or [[bruit]] differentiate it from [[Aneurysm|carotid aneurysm]].
* Normal overlying skin.
* Normal overlying skin.
| align="center" style="background:#F5F5F5;" |Normal and mobile overlying skin
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |Secretory tumors are diagnosed by biochemical testing using  [[Metaiodobenzylguanidine]] (MIBG) , followed by [[imaging]] to locate the [[tumor]]
| align="center" style="background:#F5F5F5;" |Secretory tumors are diagnosed by biochemical testing using  [[Metaiodobenzylguanidine]] (MIBG) , followed by [[imaging]] to locate the [[tumor]]
| align="center" style="background:#F5F5F5;" |Normal
| align="center" style="background:#F5F5F5;" |Normal
Line 1,811: Line 1,770:
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" | ±
| align="center" style="background:#F5F5F5;" |Non-[[Tenderness|tender]] [[mass]] in the [[neck]] or non-tender [[lymphadenopathy]]
| align="center" style="background:#F5F5F5;" |Non-[[Tenderness|tender]] [[mass]] in the [[neck]] or non-tender [[lymphadenopathy]]
| align="center" style="background:#F5F5F5;" |Normal skin
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |Majority of metastatic [[head and neck cancer]] metastatise from [[Gastrointestinal tract|GIT]] and lungs and are [[Squamous cell carcinoma|squamous cell caners]]
| align="center" style="background:#F5F5F5;" |Majority of metastatic [[head and neck cancer]] metastatise from [[Gastrointestinal tract|GIT]] and lungs and are [[Squamous cell carcinoma|squamous cell caners]]
| align="center" style="background:#F5F5F5;" |Vary depending on the underlying [[cancer]]
| align="center" style="background:#F5F5F5;" |Vary depending on the underlying [[cancer]]
Line 1,840: Line 1,798:


* Examination of [[laryngeal cancer]] is done using flexible [[laryngoscopy]] under [[anesthesia]].
* Examination of [[laryngeal cancer]] is done using flexible [[laryngoscopy]] under [[anesthesia]].
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Smoking]] is the most common risk factor
* [[Smoking]] is the most common risk factor
Line 1,874: Line 1,831:


* [[Bruit]]
* [[Bruit]]
| align="center" style="background:#F5F5F5;" |Intact overlying skin with normal color and texture
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |May be associated with [[vasculopathies]] and [[metastatic]] invasion of vessels and neck surgery
| align="center" style="background:#F5F5F5;" |May be associated with [[vasculopathies]] and [[metastatic]] invasion of vessels and neck surgery
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 1,908: Line 1,864:
* Depending on the type may be mobile or adherent to the underlying structure
* Depending on the type may be mobile or adherent to the underlying structure
* [[Lymphadenopathy]] in case of [[malignant]] features
* [[Lymphadenopathy]] in case of [[malignant]] features
| align="center" style="background:#F5F5F5;" |Intact
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" |[[Goiter]] is most commonly associated with [[iodine deficiency]]
| align="center" style="background:#F5F5F5;" |[[Goiter]] is most commonly associated with [[iodine deficiency]]
Line 1,932: Line 1,886:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mass exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mass exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin changes
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |LAP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |LAP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Others
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Others

Revision as of 16:05, 15 February 2019

Neck masses Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Neck Masses from other Conditions

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Neck masses differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Neck masses differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neck masses differential diagnosis

CDC on Neck masses differential diagnosis

Neck masses differential diagnosis in the news

Blogs on Neck masses differential diagnosis

Directions to Hospitals Treating Neck masses

Risk calculators and risk factors for Neck masses differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Neck masses must be differentiated from congenital abnormalities, inflammatory, and malignant lesions.

Differentiating neck masses from other Diseases

Neck masses must be differentiated from congenital abnormalities, inflammatory, and malignant lesions.

Category Diseases Benign/Malignant Clinical manifestation Paraclinical findings Gold standard diagnosis Associated findings
Demography History Symptoms Signs Lab findings Histopathology Imaging
Pain Dysphagia Mass exam LAP Others
Congenital Branchial cleft cyst[1]
  • Age: 1-15 years old
  • Familial occurrence
  • Lateral neck mass
±
  • Solitary
  • Smooth
  • Mobile
  • Well-defined
  • Non-pulsatile
  • Fluctuant
  • A pit at the opening of the cyst
Thyroglossal duct cyst[2][3]
  • Age: 1-10 yrs/ varies
  • Mobile
-
Haemangioma[4]
  • Age: birth - 2 yrs
  • Presents with a flat red or purple patch
  • Regress gradually with age
  • Firm
  • Rubbery
  • Well-demarcated
  • GLUT-1
  • Vascular structures with RBC
  • MRI: With or without Gd is the modality of choice
Vascular malformations[5][6]
  • Sex: No predilection
  • AV malformations: Present with purple/red swelling
±
  • Soft
  • Compressible
  • Non-tender
  • Venous: No thrill,↑ in size on valsalva
  • Grow proportionally with age
  • Doppler ultrasound: Venous malformations show slow flow, hypoechoic, AV malformations show high flow
  • MRI with Gd: Diffuse enhancement
  • MRI
-
Lymphatic malformations[7][8]
  • Age: Birth - 5yrs
  • Sex: No predilection
+
  • Soft
  • Non-compressible
  • Non-pulsatile
  • Fluctuant
  • Positive D2-40 stain
  • Ultrasound: Hypo/anechoic with thick septa and fluid
  • CT: Homogeneous and cystic mass
  • MRI: Hyperintense on T2 & peripheral wall enhancement on T1
Laryngocele[9][10][11]
  • More common in adults
  • Episodic in nature
+
  • Soft
  • Reducible
  • Common in glass blowers, trumpet players
-
Ranula[12][13]
  • Age: 1st and 2nd decade
  • Well circumscribed
  • Fluctuant
  • Soft
H&E: Shows mucin surrounded by inflammatory cells & fibrosis CT: Shows cystic mass with tail sign -
Teratoma[14][15]
  • Sex: No predilection
  • Firm
  • Non-tender
-
  • High ALP levels
  • Shows ecto, meso and endodermal tissues
Dermoid cyst[16][17]
  • Age: birth - 5 yrs
  • Freely mobile
  • Solitary
  • Rubbery
  • Nonpulsatile
  • Noncompressible
  • Usually normal/sometimes a pit or sinus is seen
-
  • CT: With contrast well circumscribed, unilocular, sac-of-marbles appearance due to fatty tissue
Thymic cyst[18]
  • Presents as a soft mass, gradually enlarging, on left side of the neck(usual)
  • Soft
  • Compressible
- -
  • CT: Uni/multilocular, well circumscribed and nonenhancing
Category Diseases Benign Demography History Pain Dysphagia Mass exam LAP Others Lab findings Histopathology Imaging Gold standard diagnosis Associated findings
Inflammatory Acute sialadenitis [19]
  • Age:Occurs in all age groups
  • Sex: No predilection
+ -
  • Firm
Inflammatory infiltrate with microabscess formation CT scan
Chronic sialadenitis[20]
  • Age:Occurs in all age groups
  • Sex: No predilection
  • Presents with an unilateral swelling
  • Recurrent episodes common
+ -
  • Non-tender
  • Firm
  • Smooth
Hyperplastic lymphoid infiltrates with loss of salivary gland acini

Fibrosis

X-ray: Shows radiopaque stones

CT: Parenchymal volume is ↓

CT scan
Reactive viral lymphadenopathy CMV[21]
  • Age: 10-35 yrs mainly
  • Sex: No predilection
  • Flu-like illness
  • Non-tender
  • Soft
  • Generalized/cervical lymphadenopathy
ESR

SGOT/SGPT

  • H&E stain: Typical owl-eye inclusions(nuclear)
Usually not necessary
EBV[22][23]
  • Age: Mainly adolescents
  • Sex: No predilection
  • Non-tender
  • Firm
  • + Monospot test
Usually not necessary
HIV[24] Benign Prevalence: 1.1 million in U.S

Sex: Males>females

  • Flu-like illness
Non-tender
  • Generalized lymphadenopathy
CD4+ Tcells

Thrombocytopenia

Anemia

AST/ALT

CRP

ESR

Lymphoid hyperplasia Usually not necessary Western blot & P24 antigen assay
Viral URI [25] Incidence: More in fall & winter

Age: Common in elderly and infants

  • Non-tender
  • Mild cervical lymphadenopathy
Inflammatory infiltrate
  • No specific findings
-
Bacterial lymphadenopathy Tularemia[26][27]
  • Age: Affects all age groups
  • Sex: No predilection
+ -
  • Edematous
  • No specific findings
Brucellosis[28]
  • Flu-like illness
+ -
  • Cervical lymphadenopathy
ESR
  • No specific findings
Serology
Cat-scratch disease[29][30]
  • More common in the Southern of U.S among children and young adults.
  • Cat exposure
+ -

Serology:

- -
Actinomycosis[31][32]
  • Tender at the beginning
  • Fluctuant
  • Non-tender at late stage
  • Red
  • Blue

Gram stains:

-
Mycobacterial infections[22][33][34]
  • Firm
  • Non-tender
  • Lymphadenopathy

Sputum smear:

  • Fusion tendency
  • Internal echoes
-
Streptococcal infection[21][35] + +
  • Lymphadenopathy
-
Parasitic lymphadenopathy Toxoplasma gondii[36][37]
  • 6 years old and older adults are more affected in U.S.
  • Seen in Hot climates
  • Undercooked food
+
  • Bilateral
  • Non-tender
  • Symmetrical
  • Non-fluctuant
  • Lymphadenopathy

+ IgG and IgM antibodies

MRI:

MRI

-
Sarcoidosis[38][19]
  • More common in African American women aged 20 - 40 years.
  • Bilateral

tender lymph nodes

  • Lupus pernios
  • Lymphadenopathy
Sjögren syndrome[39]
  • May happen at any age
  • Mean age: 40-50
  • History of RA, SLE, and non-hodgkin B-cell lymphoma.
+
  • Firm,
  • Dry
  • Lymphadenopathy
  • Anti-SSA/Ro: +
  • Anti-SSB/La: +
-
Castleman disease (angiofollicular lymphoproliferative disease)[40][41] Mean age: 30-40 years
  • B-symptoms
  • Lymphadenopathy
CT scan of thorax
Kikuchi disease (histiocytic necrotizing lymphadenitis)[42]
  • More common in young adults <30 years old
  • Flu-like prodrome
+
  • Skin rash
  • Lymphadenopathy
-
Kimura disease[43]
  • More common in Asian males.
  • Large
Eosinophils -
Rosai-Dorfman disease[44][45] - - - -
Kawasaki disease[46][47]
  • More common in children younger than 5 years old.
  • Inflammation of lips
Echocardiography:

dilation

Category Diseases Benign or Malignant Demography History Pain Dysphagia Mass exam LAP Others Lab findings Histopathology Imaging Gold standard diagnosis Associated findings
Neoplasm Hypopharyngeal cancer[48][49][50]
  • More common in males
  • Age: 55-65 years old
  • Incidence: < 1/100,000 in U.S.
  • More common: Japan, India, Iran
+ - Neck CT scan:

MRI:

  • Tumors are hypointense on T1 and hyperintense on T2
-
Salivary gland neoplasm Pleomorphic adenoma[51]
  • More common in Females
+
  • Firm
  • Mobile
- -
  • Abundant myxochondroid stroma on T2
-
Warthin's tumor[53][54]
  • More common in people aged 60 to 70 years old.
+
  • Non tender
  • Mobile
  • Firm
- - Neck CT:

MRI:

  • B/L lesions

Heterogeneous

Oncocytoma

[55]

Benign
  • Race: Caucasian patients predilection
  • Gender: No gender preference
  • Age: 50–70 years
± ± Firm, multilobulated and mobile mass
  • Normal
  • Normal
Epithelial cells with eosinophilic granular cytoplasm rich in mitochondria
  • CT:
    • Isodense expansive mass
    • Enhancement after intravenous contrast
    • Hypodense areas
  • MRI:
    • Isodensties on T1
    • Mass is hyperintense on T2
    • Enhancement on contrast
Incisional biopsy and histopathological examination
Monomorphic adenoma [56][57][58] Benign or malignant
  • Age: From 26 to 76 years
  • Rare in children
  • Sex: No sex predilection
± ± Nodular and fluctuant swelling
  • Normal
Normal Ultrasound:
  • Used to biopsy the lesion
  • May show cystic an solid components

CT:

MRI:

Incisional biopsy and histopathological examination
Mucoepidermoid carcinoma

[59]

Malignant
  • Age:: Mean age of 59
  • Gender: Female predilection
± ± Cystic and solid mass
  • May have lymphadenopathy
Gross findings:
  • Firm
  • Tan-white to yellow
  • Bosselated
  • Cystic

Microscopic findings:

cystic and solid component with variable appearance Incisional biopsy and histopathological examination Association with CMV
Adenoid cystic carcinoma [60] Malignant Age: 40s to 60s

Gender: Female predominance

± ± Solid mass Gross findings: Tubular, cribriform and solid pattern of growth

Microscopic findings: Components of large cells with pleomorphic nuclei

increased mitotic activity, and focal necrosis.

Imaging reveal dimensions of the tumor, local spread and distant metastasis Biopsy and histopathological examination
Adenocarcinoma

[61]

Malignant Age: young age predilection Its a tumor of minor salivary glands so may present as small ulceration or nodules in oral cavity Small nodules and oral cavity with or without lymphadenopathy Can be normal or may show anemia and blood cell disorders with distant bone invasion On histology it is confused with Adeocyctic carcinoma with components of gland and cyst formations.

It has more perineural invasion.

CT and MRI both can be used to visualize the tumor. MRI being more accurate for adjacent tissue involvement and lymphadenopathy. Biopsy and histopathological examination
Salivary duct cancer

[62][63][64]

Malignant

(Highly aggressive)

Incidence: 1% to 3%

Gender: Men

Mean age: 55 to 61 years

  • Rapidly growing mass with jaw involvement
± ±
  • Painless, hard and non-compressible mass
Pathomorphologically tumor of salivary ducts resembles tumor of breast ducts, and that where it name is derived from Gross findings:

Microscopic finding:

  • Microscopically it resembles ductal carcinoma of breast
  • Intraductal components invading surrounding tissues
  • Intra-ductal component of tumor arrange in several forms: cribriform, papillary, solid with comedo-like central necrosis
Non-specific features on CT and MRI but it can show neural and jaw involvement. Biopsy and histopathological examination
Squamous cell carcinoma

[65][66]

Malignant Incidence: rare tumor

Age: Old age , 61 to 68 years

Gender: Male predilection

Present as painful growing mass on jaw + Submandibular gland predilection

Thinning and discoloration of skin

Past radiation exposure is a strong risk factor Gross findings: Shows skin tissue and thinning of skin

Microscopically findings:

Nest and solid sheets of tumor cells arranged in glandular pattern. It is derived from epidermoid cells of salivary gland.

May show vascular invasion and inflammatory infiltrate.

Immunohistochemical staining can be used to mark the squamous and keratin component.

Tumor dimension can be delineated using both CT and MRI Biopsy and histopathological examination
Parathyroid cancer

[67][68][69]

Malignant Incidence: Rare

Mean age : 44 to 54 years

Gender: Female predilection

+ + Lower neck mass Microscopic findings:Tumor shows trabecular growth pattern with high mitosis and surrounding thick fibrous bands. Capsular involvement and vascular invasion is common Biopsy and histopathological examination
Carotid body tumors

[70][71][72][73]

Benign
  • Age: 26-55 years
  • Male predominance
+ May show Increased catecholamine levels Microscopically they are extra- adrenal paragangliomas Histopathology analysis and catecholamine levels
Paraganglioma

[74][75][76]

Benign (Majority)

Malignant (rare)

  • Age 50-70 years
  • More in females
May be an accidental finding depending on their secretory nature or present with following symptoms:

Catecholaminesecreting paragangliomas present with :

No visible mass as they are located deep in the the neck along the glossopharyngeal and vagal nerves. Associated with some hereditary syndromes and MEN2B syndrome, Neurofibromatosis type 1 and VHL disease Biochemical testing may show catecholamine metabolites in serum or urine samples These are highly vascular tumors that involves nerves around vessels

Gross findings:

  • Pink to red brown to gray in color

Microscopic findings:

Round or polygonal cells arranged inside capsule in the form of nests or forming trabecular structures.

Differentiation between benign or malignancy form is done depending microscopic features of invasion and high mitotic index

Following imaging techniques can be used to diagnose the tumor:

As these are secretory tumors further testing with following techniques can confirm diagnoses:

Imaging and serum catecholamine analysis
Schwannoma

[77][78][79]

Benign Rare tumor

Incidence: 1% to 10%

Slow growing mass presents with the localized neural deficit depending on the site of peripheral nerve involved.

Vagal involvement:

Sympathetic nerve involvement may present as Horner's syndrome:

Vestibular Schwannoma (most common):

+ ± Multiple slow growing nodules on the skin Associated with neurofibromatosis type II.

Most common nerve involved in vestibular nerve

May be normal

vagus nerve or superior cervical sympathetic chain being most common locations.

  • Histology shows encapsulated neural tissue growth.
Imaging can diagnose the tumor. Its hard to discriminate Carotid body tumor from Schwannoma on CT. MRI and MRI angiography can confirm the diagnoses. Imaging is used for diagnoses
Lymphoma [80][81]

[82][83][84][85]

Benign/ malignant Age: Predilection for older age

Mean age: 55

±
  • Tissue biopsy is used for diagnose.
  • On complete node analysis four patterns are described:
    • Nodular/follicular
    • Diffuse pattern
    • Transition from a nodular to a diffuse pattern in adjacent nodes
    • Transition from a lower to a higher grade of involvement within a single node
Lymph node biopsy coupled with cytometry
Liposarcoma [86][87]

[88][89]

Malignant Rare tumors

Age: Relatively in older age

Gender: No gender predilection

Mobile masses with very few symptoms until they grow enough to compress the surrounding structures, which produces symptoms of neural deficit, pain, tingling or skin changes. ± Mobile soft mass with intact overlying skin and in some cases with blue discoloration due to intra-lesion hemorrhage
  • Intact skin and normal color
Normal Gross findings:

Bulk of yellow colored fat tissue.

Microscopic features:

Adipose tissue containing that containing lipoblasts atypical nucleus pushed to side by intracytoplasmic vacuoles.

Tissue biopsy may show histological sub-groups:

  • Well-differentiated
  • Myxoid/round cell
  • Pleomorphic liposarcomas
Imaging is not usually used for diagnoses except to look for deeper invasion.

Ultrasound shows homogeneous hyperechoic mass.

Biopsy and histopathology analysis
Lipoma [90][91][92] Benign One or multiple soft, painless skin nodules.

May causes pain or compressive symptoms

± Mobile soft nodule with intact overlying skin
  • Intact skin and normal color
Normal Diagnoses is usually clinical but tissue biopsy may show

Bundle of well-demarcated lipocytes with single nuclei aligned to the side and intra-cytoplasimic fat granules.

Diagnoses is usually clinical but ultrasound is used to differentiate lipoma from other benign lesions such as epidermoid cyst or a ganglion.

Clinical evaluation

and tissue biopsy

Multiple lipomas are associated with familial multiple lipomatosis
Glomus vagale, glomus jugulare tumors

[93][94][95][96]

[97][98]

Benign

Rare tumor

- ± Secretory tumors are diagnosed by biochemical testing using Metaiodobenzylguanidine (MIBG) , followed by imaging to locate the tumor Normal
  • Imaging is important for the diagnosis.
  • Imaging of choice is MRI.
  • MRI may show typical appearance of the tumor along Vagus nerve.
  • USG may used to see the tumor but it is for early stage of diagnoses.
  • US shows isoechoic to hypoechoic well defined tumor.
  • CT can show vascularity of tumor.
  • Biochemical testing to see secretary nature of tumor
Imaging and MIBG testing
Metastatic head and neck cancer

[99][100]

Malignant Depends on the nature of metastatic tumor - ± Non-tender mass in the neck or non-tender lymphadenopathy Majority of metastatic head and neck cancer metastatise from GIT and lungs and are squamous cell caners Vary depending on the underlying cancer Histology of primary cancer CT and MRI shows extend of the tumor and other regions of metastasis Biopsy and histopathology of the primary site of tumor
Other Laryngeal cancer

[101][102]

Benign/Malignant
  • Older males
  • Younger patients with HPV infection or smoking history
± ±

human papillomavirus (HPV) infection

HPV testing may show HPV infection FNA of neck mass followed by biopsy is done to diagnose laryngeal cancer. It show type cancerous cells.
  • Panendoscopy is done to see extent of the tumor.
Laryngoscopy and biopsy
Arteriovenous fistula

[103][104]

Benign/Malignant Depends on the risk factors - - May be associated with vasculopathies and metastatic invasion of vessels and neck surgery Varies depending on the etiology MR angiography may be used to visualize the tract MR angiography
Thyroid nodule/ Goiter

[105][106][107][108]

Benign/ Malignant
  • Female predominance
  • Young age (benign causes)
  • Palpitation
± ±
  • Painless non-tender and asymmetrical neck mass in front of neck with smooth overlying skin and nodular surface
  • Depending on the type may be mobile or adherent to the underlying structure
  • Lymphadenopathy in case of malignant features
- Goiter is most commonly associated with iodine deficiency
  • High TSH levels in case of goiter
FNA is done in case of goiter and core biopsy is performed if malignancy is suspected USG: Shows nodular or non- nodular lesions in Thyroid. US is better than CT.

Thyroid radionuclide imaging: Shows radioiodine uptake and is usually cold in case of malignancy and may be cold or hot in case of goiter.

Biopsy and histopathology of nodules
Category Diseases Benign Demography History Pain Dysphagia Mass exam LAP Others Lab findings Histopathology Imaging Gold standard diagnosis Associated findings

References

  1. Nahata, Vaishali (2016). "Branchial cleft cyst". Indian Journal of Dermatology. 61 (6): 701. doi:10.4103/0019-5154.193718. ISSN 0019-5154.
  2. Amos J, Shermetaro C. PMID 30085599. Missing or empty |title= (help)
  3. Deaver MJ, Silman EF, Lotfipour S (August 2009). "Infected thyroglossal duct cyst". West J Emerg Med. 10 (3): 205. PMC 2729228. PMID 19718389.
  4. Léauté-Labrèze, C.; Prey, S.; Ezzedine, K. (2011). "Infantile haemangioma: Part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities". Journal of the European Academy of Dermatology and Venereology. 25 (11): 1245–1253. doi:10.1111/j.1468-3083.2011.04102.x. ISSN 0926-9959.
  5. Cox JA, Bartlett E, Lee EI (May 2014). "Vascular malformations: a review". Semin Plast Surg. 28 (2): 58–63. doi:10.1055/s-0034-1376263. PMC 4078214. PMID 25045330.
  6. Behravesh S, Yakes W, Gupta N, Naidu S, Chong BW, Khademhosseini A, Oklu R (December 2016). "Venous malformations: clinical diagnosis and treatment". Cardiovasc Diagn Ther. 6 (6): 557–569. doi:10.21037/cdt.2016.11.10. PMC 5220204. PMID 28123976.
  7. Cox JA, Bartlett E, Lee EI (May 2014). "Vascular malformations: a review". Semin Plast Surg. 28 (2): 58–63. doi:10.1055/s-0034-1376263. PMC 4078214. PMID 25045330.
  8. Guruprasad Y, Chauhan DS (September 2012). "Cervical cystic hygroma". J Maxillofac Oral Surg. 11 (3): 333–6. doi:10.1007/s12663-010-0149-x. PMC 3428451. PMID 23997487.
  9. Werner RL, Schroeder JW, Castle JT (March 2014). "Bilateral laryngoceles". Head Neck Pathol. 8 (1): 110–3. doi:10.1007/s12105-013-0478-4. PMC 3950389. PMID 23881550.
  10. Prasad KC, Vijayalakshmi S, Prasad SC (December 2008). "Laryngoceles - presentations and management". Indian J Otolaryngol Head Neck Surg. 60 (4): 303–8. doi:10.1007/s12070-008-0108-8. PMC 3476818. PMID 23120570.
  11. Mahdoufi R, Barhmi I, Tazi N, Abada R, Roubal M, Mahtar M (July 2017). "Mixed Pyolaryngocele: A Rare Case of Deep Neck Infection". Iran J Otorhinolaryngol. 29 (93): 225–228. PMC 5554815. PMID 28819622.
  12. Packiri S, Gurunathan D, Selvarasu K (September 2017). "Management of Paediatric Oral Ranula: A Systematic Review". J Clin Diagn Res. 11 (9): ZE06–ZE09. doi:10.7860/JCDR/2017/28498.10622. PMC 5713871. PMID 29207849.
  13. Kokong D, Iduh A, Chukwu I, Mugu J, Nuhu S, Augustine S (June 2017). "Ranula: Current Concept of Pathophysiologic Basis and Surgical Management Options". World J Surg. 41 (6): 1476–1481. doi:10.1007/s00268-017-3901-2. PMC 5422487. PMID 28194490.
  14. Chauhan DS, Guruprasad Y, Inderchand S (September 2011). "Congenital nasopharyngeal teratoma with a cleft palate: case report and a 7 year follow up". J Maxillofac Oral Surg. 10 (3): 253–6. doi:10.1007/s12663-010-0140-6. PMC 3238564. PMID 22942597.
  15. Bahgat M, Bahgat Y, Bahgat A (July 2012). "Oropharyngeal teratoma, a rare cause of airway obstruction in neonates". BMJ Case Rep. 2012. doi:10.1136/bcr-2012-006580. PMC 4543570. PMID 22814615.
  16. Paradis, Josée; Koltai, Peter J. (2015). "Pediatric Teratoma and Dermoid Cysts". Otolaryngologic Clinics of North America. 48 (1): 121–136. doi:10.1016/j.otc.2014.09.009. ISSN 0030-6665.
  17. Gaddikeri S, Vattoth S, Gaddikeri RS, Stuart R, Harrison K, Young D, Bhargava P (2014). "Congenital cystic neck masses: embryology and imaging appearances, with clinicopathological correlation". Curr Probl Diagn Radiol. 43 (2): 55–67. doi:10.1067/j.cpradiol.2013.12.001. PMID 24629659.
  18. Gaddikeri, Santhosh; Vattoth, Surjith; Gaddikeri, Ramya S.; Stuart, Royal; Harrison, Keith; Young, Daniel; Bhargava, Puneet (2014). "Congenital Cystic Neck Masses: Embryology and Imaging Appearances, With Clinicopathological Correlation". Current Problems in Diagnostic Radiology. 43 (2): 55–67. doi:10.1067/j.cpradiol.2013.12.001. ISSN 0363-0188.
  19. 19.0 19.1 Abdel Razek A, Mukherji S (June 2017). "Imaging of sialadenitis". Neuroradiol J. 30 (3): 205–215. doi:10.1177/1971400916682752. PMC 5480791. PMID 28059621. Vancouver style error: initials (help)
  20. Orlandi MA, Pistorio V, Guerra PA (2013). "Ultrasound in sialadenitis". J Ultrasound. 16 (1): 3–9. doi:10.1007/s40477-013-0002-4. PMC 3774898. PMID 24046793.
  21. 21.0 21.1 Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A (March 2014). "Peripheral lymphadenopathy: approach and diagnostic tools". Iran J Med Sci. 39 (2 Suppl): 158–70. PMC 3993046. PMID 24753638.
  22. 22.0 22.1 Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A (March 2014). "Peripheral lymphadenopathy: approach and diagnostic tools". Iran J Med Sci. 39 (2 Suppl): 158–70. PMC 3993046. PMID 24753638.
  23. Stuhlmann-Laeisz C, Oschlies I, Klapper W (December 2014). "Detection of EBV in reactive and neoplastic lymphoproliferations in adults-when and how?". J Hematop. 7 (4): 165–170. doi:10.1007/s12308-014-0209-0. PMC 4243011. PMID 25478033.
  24. Moonim MT, Alarcon L, Freeman J, Mahadeva U, van der Walt JD, Lucas SB (March 2010). "Identifying HIV infection in diagnostic histopathology tissue samples--the role of HIV-1 p24 immunohistochemistry in identifying clinically unsuspected HIV infection: a 3-year analysis". Histopathology. 56 (4): 530–41. doi:10.1111/j.1365-2559.2010.03513.x. PMID 20459560.
  25. Thomas M, Bomar PA. PMID 30422556. Missing or empty |title= (help)
  26. Grunow R, Splettstoesser W, McDonald S, Otterbein C, O'Brien T, Morgan C, Aldrich J, Hofer E, Finke EJ, Meyer H (January 2000). "Detection of Francisella tularensis in biological specimens using a capture enzyme-linked immunosorbent assay, an immunochromatographic handheld assay, and a PCR". Clin. Diagn. Lab. Immunol. 7 (1): 86–90. PMC 95828. PMID 10618283.
  27. Koç, Sema (2012). "Clinical and laboratory findings of tularemia: a retrospective analysis". The Turkish Journal of Ear Nose and Throat: 26–31. doi:10.5606/kbbihtisas.2012.005. ISSN 1300-7475.
  28. Golshani M, Buozari S (November 2017). "A review of Brucellosis in Iran: Epidemiology, Risk Factors, Diagnosis, Control, and Prevention". Iran. Biomed. J. 21 (6): 349–59. PMC 5572431. PMID 28766326.
  29. "Cat-Scratch Disease in the United States, 2005–2013 - Volume 22, Number 10—October 2016 - Emerging Infectious Diseases journal - CDC".
  30. Hansmann, Y.; DeMartino, S.; Piemont, Y.; Meyer, N.; Mariet, P.; Heller, R.; Christmann, D.; Jaulhac, B. (2005). "Diagnosis of Cat Scratch Disease with Detection of Bartonella henselae by PCR: a Study of Patients with Lymph Node Enlargement". Journal of Clinical Microbiology. 43 (8): 3800–3806. doi:10.1128/JCM.43.8.3800-3806.2005. ISSN 0095-1137.
  31. Valour F, Sénéchal A, Dupieux C, Karsenty J, Lustig S, Breton P, Gleizal A, Boussel L, Laurent F, Braun E, Chidiac C, Ader F, Ferry T (2014). "Actinomycosis: etiology, clinical features, diagnosis, treatment, and management". Infect Drug Resist. 7: 183–97. doi:10.2147/IDR.S39601. PMC 4094581. PMID 25045274.
  32. Bonnefond S, Catroux M, Melenotte C, Karkowski L, Rolland L, Trouillier S, Raffray L (June 2016). "Clinical features of actinomycosis: A retrospective, multicenter study of 28 cases of miscellaneous presentations". Medicine (Baltimore). 95 (24): e3923. doi:10.1097/MD.0000000000003923. PMC 4998488. PMID 27311002.
  33. Suskind DL, Handler SD, Tom LW, Potsic WP, Wetmore RF (July 1997). "Nontuberculous mycobacterial cervical adenitis". Clin Pediatr (Phila). 36 (7): 403–9. doi:10.1177/000992289703600705. PMID 9241478.
  34. Drobniewski FA, Caws M, Gibson A, Young D (March 2003). "Modern laboratory diagnosis of tuberculosis". Lancet Infect Dis. 3 (3): 141–7. PMID 12614730.
  35. Kenealy T (November 2007). "Sore throat". BMJ Clin Evid. 2007. PMC 2943825. PMID 19450346.
  36. Kumar GG, Mahadevan A, Guruprasad AS, Kovoor JM, Satishchandra P, Nath A, Ranga U, Shankar SK (June 2010). "Eccentric target sign in cerebral toxoplasmosis: neuropathological correlate to the imaging feature". J Magn Reson Imaging. 31 (6): 1469–72. doi:10.1002/jmri.22192. PMC 2908244. PMID 20512900.
  37. [+https://www.cdc.gov/parasites/toxoplasmosis/diagnosis.html "CDC - Toxoplasmosis - Diagnosis"] Check |url= value (help).
  38. "Sarcoidosis | National Heart, Lung, and Blood Institute (NHLBI)".
  39. Mavragani CP, Moutsopoulos HM (October 2014). "Sjögren syndrome". CMAJ. 186 (15): E579–86. doi:10.1503/cmaj.122037. PMC 4203623. PMID 24566651.
  40. Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, Menke DM, Weisenburger DD, Ristow K, Dogan A, Habermann TM (November 2012). "The clinical spectrum of Castleman's disease". Am. J. Hematol. 87 (11): 997–1002. doi:10.1002/ajh.23291. PMC 3900496. PMID 22791417.
  41. Saeed-Abdul-Rahman I, Al-Amri AM (September 2012). "Castleman disease". Korean J Hematol. 47 (3): 163–77. doi:10.5045/kjh.2012.47.3.163. PMC 3464333. PMID 23071471.
  42. Bosch X, Guilabert A (May 2006). "Kikuchi-Fujimoto disease". Orphanet J Rare Dis. 1: 18. doi:10.1186/1750-1172-1-18. PMC 1481509. PMID 16722618.
  43. AlGhamdi FE, Al-Khatib TA, Marzouki HZ, AlGarni MA (March 2016). "Kimura disease: No age or ethnicity limit". Saudi Med J. 37 (3): 315–9. doi:10.15537/smj.2016.3.14448. PMC 4800898. PMID 26905356.
  44. "Rosai-Dorfman disease | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program".
  45. Foucar E, Rosai J, Dorfman R (February 1990). "Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity". Semin Diagn Pathol. 7 (1): 19–73. PMID 2180012.
  46. "About Kawasaki Disease | Kawasaki Disease | CDC".
  47. "Kawasaki Disease | National Heart, Lung, and Blood Institute (NHLBI)".
  48. Helliwell TR (February 2003). "acp Best Practice No 169. Evidence based pathology: squamous carcinoma of the hypopharynx". J. Clin. Pathol. 56 (2): 81–5. PMC 1769882. PMID 12560383.
  49. International Journal of Recent Scientific Research. doi:10.24327/IJRSR. ISSN 0976-3031. Missing or empty |title= (help)
  50. Maasland, Denise HE; van den Brandt, Piet A; Kremer, Bernd; Goldbohm, R Alexandra; Schouten, Leo J (2014). "Alcohol consumption, cigarette smoking and the risk of subtypes of head-neck cancer: results from the Netherlands Cohort Study". BMC Cancer. 14 (1). doi:10.1186/1471-2407-14-187. ISSN 1471-2407.
  51. Debnath SC, Adhyapok AK (June 2010). "Pleomorphic adenoma (benign mixed tumour) of the minor salivary glands of the upper lip". J Maxillofac Oral Surg. 9 (2): 205–8. doi:10.1007/s12663-010-0052-5. PMC 3244097. PMID 22190789.
  52. Kato H, Kawaguchi M, Ando T, Mizuta K, Aoki M, Matsuo M (August 2018). "Pleomorphic adenoma of salivary glands: common and uncommon CT and MR imaging features". Jpn J Radiol. 36 (8): 463–471. doi:10.1007/s11604-018-0747-y. PMID 29845358.
  53. Chulam TC, Noronha Francisco AL, Goncalves Filho J, Pinto Alves CA, Kowalski LP (December 2013). "Warthin's tumour of the parotid gland: our experience". Acta Otorhinolaryngol Ital. 33 (6): 393–7. PMID 24376295.
  54. "Warthin tumor | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program".
  55. Chen B, Hentzelman JI, Walker RJ, Lai JP (2016). "Oncocytoma of the Submandibular Gland: Diagnosis and Treatment Based on Clinicopathology". Case Rep Otolaryngol. 2016: 8719030. doi:10.1155/2016/8719030. PMC 5045990. PMID 27722003.
  56. Kim KH, Sung MW, Kim JW, Koo JW (July 2000). "Pleomorphic adenoma of the trachea". Otolaryngol Head Neck Surg. 123 (1 Pt 1): 147–8. doi:10.1067/mhn.2000.102809. PMID 10889498.
  57. Pramod Krishna B (June 2013). "Pleomorphic Adenoma of Minor Salivary Gland in a 14 year Old Child". J Maxillofac Oral Surg. 12 (2): 228–31. doi:10.1007/s12663-010-0125-5. PMC 3681990. PMID 24431845.
  58. Kessler AT, Bhatt AA (2018). "Review of the Major and Minor Salivary Glands, Part 2: Neoplasms and Tumor-like Lesions". J Clin Imaging Sci. 8: 48. doi:10.4103/jcis.JCIS_46_18. PMC 6251244. PMID 30546932.
  59. Chenevert J, Barnes LE, Chiosea SI (February 2011). "Mucoepidermoid carcinoma: a five-decade journey". Virchows Arch. 458 (2): 133–40. doi:10.1007/s00428-011-1040-y. PMID 21243374.
  60. Jones AV, Craig GT, Speight PM, Franklin CD (April 2008). "The range and demographics of salivary gland tumours diagnosed in a UK population". Oral Oncol. 44 (4): 407–17. doi:10.1016/j.oraloncology.2007.05.010. PMID 17825603.
  61. Beltran D, Faquin WC, Gallagher G, August M (March 2006). "Selective immunohistochemical comparison of polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma". J. Oral Maxillofac. Surg. 64 (3): 415–23. doi:10.1016/j.joms.2005.11.027. PMID 16487803.
  62. Mlika M, Kourda N, Zidi Y, Aloui R, Zneidi N, Rammeh S, Zermani R, Jilani SB (January 2012). "Salivary duct carcinoma of the parotid gland". J Oral Maxillofac Pathol. 16 (1): 134–6. doi:10.4103/0973-029X.92992. PMC 3303509. PMID 22434951.
  63. Schmitt NC, Kang H, Sharma A (November 2017). "Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy". Oral Oncol. 74: 40–48. doi:10.1016/j.oraloncology.2017.09.008. PMC 5685667. PMID 29103750.
  64. Simpson RH (July 2013). "Salivary duct carcinoma: new developments--morphological variants including pure in situ high grade lesions; proposed molecular classification". Head Neck Pathol. 7 Suppl 1: S48–58. doi:10.1007/s12105-013-0456-x. PMC 3712088. PMID 23821208.
  65. Manvikar V, Ramulu S, Ravishanker ST, Chakravarthy C (May 2014). "Squamous cell carcinoma of submandibular salivary gland: A rare case report". J Oral Maxillofac Pathol. 18 (2): 299–302. doi:10.4103/0973-029X.140909. PMC 4196305. PMID 25328317.
  66. Ying YL, Johnson JT, Myers EN (July 2006). "Squamous cell carcinoma of the parotid gland". Head Neck. 28 (7): 626–32. doi:10.1002/hed.20360. PMID 16475198.
  67. Wei CH, Harari A (March 2012). "Parathyroid carcinoma: update and guidelines for management". Curr Treat Options Oncol. 13 (1): 11–23. doi:10.1007/s11864-011-0171-3. PMID 22327883.
  68. Sahasranam P, Tran MT, Mohamed H, Friedman TC (August 2007). "Multiglandular parathyroid carcinoma: a case report and brief review". South. Med. J. 100 (8): 841–4. doi:10.1097/SMJ.0b013e318073ca37. PMID 17713315.
  69. Holmes EC, Morton DL, Ketcham AS (April 1969). "Parathyroid carcinoma: a collective review". Ann. Surg. 169 (4): 631–40. PMC 1387475. PMID 4886854.
  70. Sajid MS, Hamilton G, Baker DM (August 2007). "A multicenter review of carotid body tumour management". Eur J Vasc Endovasc Surg. 34 (2): 127–30. doi:10.1016/j.ejvs.2007.01.015. PMID 17400487.
  71. Boedeker CC, Ridder GJ, Schipper J (2005). "Paragangliomas of the head and neck: diagnosis and treatment". Fam. Cancer. 4 (1): 55–9. doi:10.1007/s10689-004-2154-z. PMID 15883711.
  72. Pellitteri PK, Rinaldo A, Myssiorek D, Gary Jackson C, Bradley PJ, Devaney KO, Shaha AR, Netterville JL, Manni JJ, Ferlito A (July 2004). "Paragangliomas of the head and neck". Oral Oncol. 40 (6): 563–75. doi:10.1016/j.oraloncology.2003.09.004. PMID 15063383.
  73. Darouassi Y, Alaoui M, Mliha Touati M, Al Maghraoui O, En-Nouali A, Bouaity B, Ammar H (August 2017). "Carotid Body Tumors: A Case Series and Review of the Literature". Ann Vasc Surg. 43: 265–271. doi:10.1016/j.avsg.2017.03.167. PMID 28478173.
  74. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C (August 2004). "Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations". JAMA. 292 (8): 943–51. doi:10.1001/jama.292.8.943. PMID 15328326.
  75. Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, Young WF (November 2001). "Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients". J. Clin. Endocrinol. Metab. 86 (11): 5210–6. doi:10.1210/jcem.86.11.8034. PMID 11701678.
  76. O'Riordain DS, Young WF, Grant CS, Carney JA, van Heerden JA (September 1996). "Clinical spectrum and outcome of functional extraadrenal paraganglioma". World J Surg. 20 (7): 916–21, discussion 922. PMID 8678971.
  77. Hilton DA, Hanemann CO (April 2014). "Schwannomas and their pathogenesis". Brain Pathol. 24 (3): 205–20. doi:10.1111/bpa.12125. PMID 24450866.
  78. Albert P, Patel J, Badawy K, Weissinger W, Brenner M, Bourhill I, Parnell J (2017). "Peripheral Nerve Schwannoma: A Review of Varying Clinical Presentations and Imaging Findings". J Foot Ankle Surg. 56 (3): 632–637. doi:10.1053/j.jfas.2016.12.003. PMID 28237565.
  79. Wong B, Bathala S, Grant D (January 2017). "Laryngeal schwannoma: a systematic review". Eur Arch Otorhinolaryngol. 274 (1): 25–34. doi:10.1007/s00405-016-4013-6. PMID 27020268. Vancouver style error: initials (help)
  80. Anderson T, Chabner BA, Young RC, Berard CW, Garvin AJ, Simon RM, DeVita VT (December 1982). "Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute". Cancer. 50 (12): 2699–707. PMID 7139563.
  81. Anderson T, Chabner BA, Young RC, Berard CW, Garvin AJ, Simon RM, DeVita VT (December 1982). "Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute". Cancer. 50 (12): 2699–707. PMID 7139563.
  82. Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S (August 2004). "B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review". Int. J. Cancer. 111 (1): 1–8. doi:10.1002/ijc.20205. PMID 15185336.
  83. Moormeier JA, Williams SF, Golomb HM (February 1990). "The staging of non-Hodgkin's lymphomas". Semin. Oncol. 17 (1): 43–50. PMID 2406917.
  84. Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S (August 2004). "B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review". Int. J. Cancer. 111 (1): 1–8. doi:10.1002/ijc.20205. PMID 15185336.
  85. Anderson T, Chabner BA, Young RC, Berard CW, Garvin AJ, Simon RM, DeVita VT (December 1982). "Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute". Cancer. 50 (12): 2699–707. PMID 7139563.
  86. Evans HL (January 2007). "Atypical lipomatous tumor, its variants, and its combined forms: a study of 61 cases, with a minimum follow-up of 10 years". Am. J. Surg. Pathol. 31 (1): 1–14. doi:10.1097/01.pas.0000213406.95440.7a. PMID 17197914.
  87. Conyers R, Young S, Thomas DM (2011). "Liposarcoma: molecular genetics and therapeutics". Sarcoma. 2011: 483154. doi:10.1155/2011/483154. PMC 3021868. PMID 21253554.
  88. Alaggio R, Coffin CM, Weiss SW, Bridge JA, Issakov J, Oliveira AM, Folpe AL (May 2009). "Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age". Am. J. Surg. Pathol. 33 (5): 645–58. doi:10.1097/PAS.0b013e3181963c9c. PMID 19194281.
  89. Serpell JW, Chen RY (July 2007). "Review of large deep lipomatous tumours". ANZ J Surg. 77 (7): 524–9. doi:10.1111/j.1445-2197.2007.04042.x. PMID 17610686.
  90. de Bree E, Karatzanis A, Hunt JL, Strojan P, Rinaldo A, Takes RP, Ferlito A, de Bree R (May 2015). "Lipomatous tumours of the head and neck: a spectrum of biological behaviour". Eur Arch Otorhinolaryngol. 272 (5): 1061–77. doi:10.1007/s00405-014-3065-8. PMID 24800932.
  91. Rydholm A, Berg NO (December 1983). "Size, site and clinical incidence of lipoma. Factors in the differential diagnosis of lipoma and sarcoma". Acta Orthop Scand. 54 (6): 929–34. PMID 6670522.
  92. Myhre-Jensen O (June 1981). "A consecutive 7-year series of 1331 benign soft tissue tumours. Clinicopathologic data. Comparison with sarcomas". Acta Orthop Scand. 52 (3): 287–93. PMID 7282321.
  93. Urquhart AC, Johnson JT, Myers EN, Schechter GL (April 1994). "Glomus vagale: paraganglioma of the vagus nerve". Laryngoscope. 104 (4): 440–5. doi:10.1288/00005537-199404000-00008. PMID 8164483.
  94. Valavanis A, Schubiger O, Oguz M (1983). "High-resolution CT investigation of nonchromaffin paragangliomas of the temporal bone". AJNR Am J Neuroradiol. 4 (3): 516–9. PMID 6308990.
  95. Urquhart AC, Johnson JT, Myers EN, Schechter GL (April 1994). "Glomus vagale: paraganglioma of the vagus nerve". Laryngoscope. 104 (4): 440–5. doi:10.1288/00005537-199404000-00008. PMID 8164483.
  96. Stein PP, Black HR (January 1991). "A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution's experience". Medicine (Baltimore). 70 (1): 46–66. PMID 1988766.
  97. Sajid MS, Hamilton G, Baker DM (August 2007). "A multicenter review of carotid body tumour management". Eur J Vasc Endovasc Surg. 34 (2): 127–30. doi:10.1016/j.ejvs.2007.01.015. PMID 17400487.
  98. Boedeker CC, Ridder GJ, Schipper J (2005). "Paragangliomas of the head and neck: diagnosis and treatment". Fam. Cancer. 4 (1): 55–9. doi:10.1007/s10689-004-2154-z. PMID 15883711.
  99. Gluckman JL, Robbins KT, Fried MP (1990). "Cervical metastatic squamous carcinoma of unknown or occult primary source". Head Neck. 12 (5): 440–3. PMID 2211107.
  100. Waltonen JD, Ozer E, Hall NC, Schuller DE, Agrawal A (October 2009). "Metastatic carcinoma of the neck of unknown primary origin: evolution and efficacy of the modern workup". Arch. Otolaryngol. Head Neck Surg. 135 (10): 1024–9. doi:10.1001/archoto.2009.145. PMID 19841343.
  101. Feldman PS, Kaplan MJ, Johns ME, Cantrell RW (November 1983). "Fine-needle aspiration in squamous cell carcinoma of the head and neck". Arch Otolaryngol. 109 (11): 735–42. PMID 6639441.
  102. Grénman R, Koivunen P, Minn H (2015). "[Laryngeal cancer in Finland]". Duodecim (in Finnish). 131 (4): 331–7. PMID 26237923.
  103. Guneyli S, Cinar C, Bozkaya H, Korkmaz M, Oran I (September 2016). "Endovascular management of congenital arteriovenous fistulae in the neck". Diagn Interv Imaging. 97 (9): 871–5. doi:10.1016/j.diii.2015.08.006. PMID 26972281.
  104. Gobin YP, Garcia de la Fuente JA, Herbreteau D, Houdart E, Merland JJ (November 1993). "Endovascular treatment of external carotid-jugular fistulae in the parotid region". Neurosurgery. 33 (5): 812–6. PMID 8264877.
  105. Madjar S, Weissberg D (July 1995). "Retrosternal goiter". Chest. 108 (1): 78–82. PMID 7606997.
  106. Hedayati N, McHenry CR (March 2002). "The clinical presentation and operative management of nodular and diffuse substernal thyroid disease". Am Surg. 68 (3): 245–51, discussion 251–2. PMID 11893102.
  107. Hughes K, Eastman C (August 2012). "Goitre - causes, investigation and management". Aust Fam Physician. 41 (8): 572–6. PMID 23145396.
  108. Hermus AR, Huysmans DA (August 2000). "[Diagnosis and therapy of patients with euthyroid goiter]". Ned Tijdschr Geneeskd (in Dutch; Flemish). 144 (34): 1623–7. PMID 10972051.